SEC Filings
Lilly's $410 Million Jardiance Milestone Was The Last One — No More Payments Remain
Lilly booked $910 million in Jardiance milestones over nine months, and its 10-Q says none are left to earn.
Eli Lilly and (LLY) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Lilly booked $910 million in Jardiance milestones over nine months, and its 10-Q says none are left to earn.
Earnings
Executives pushed the obesity pill's share and a diabetes decision, while CNBC put its quarterly sales at $184 million.
Markets
Shares hit a 52-week high after Lilly raised its 2026 sales forecast, though deal charges trimmed its adjusted profit outlook.
Deals
Third-quarter revenue rose 39% on Mounjaro and Zepbound, yet acquired research charges pulled the full-year earnings range lower.